1. You are here:
  2. Homepage
  3. Working Parties
  4. Cellular Therapies
  5. About and Activities

About and Activities

Learn more about the Cellular Therapies Working Party and its activities.

About 

  • We cover all the different aspects of cellular therapies
  • We provide a platform for discussion, especially when related to transfusion and provide a resource for learning and the exchange of ideas
  • We act as an expert group to advise ISBT on matters related to cell therapy
  • We also represent ISBT on collaborative work with other international societies including AABB, ISCT, ICCBBA
  • We are available to offer expert practical and scientific advice to ISBT members who may want to start stem cell processing and cell therapy programmes

Activities and projects

Eye Drops of Human Origin (EDHO) subgroup

Work plan 2024-2025
  • Create survey regarding eye drops
  • To be sent to all ISBT members
  • Which centres make eye drops from blood products/other types of eye drops?
  • How are they made?
  • How do blood centres interact with ophthalmologists?
  • Includes questions for ophthalmologists about prescribing and efficacy
Webinar 
Timeline
Survey in development in REDCap
Send out in 2024
Analyse and prepare abstract for regional ISBT meeting 2025
 

Visit the EDHO 2022 page

Visit the EDHO 2022 page

 

Literature

Literature list EDHO

Serum eye drops: a survey of international production methods. Marks DC, van der Meer PF; Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Vox Sang. 2017 May;112(4):310-317. doi: 10.1111/vox.12502. Epub 2017 Mar 23. PMID: 28332214.

In vitro evaluation of platelet extracellular vesicles (PEVs) for corneal endothelial regeneration. Widyaningrum R, Wu YW, Delila L, Lee DY, Wang TJ, Burnouf T. Platelets. 2022 Nov 17;33(8):1237-1250. doi: 10.1080/09537104.2022.2105829. Epub 2022 Aug 10. PMID: 35949054.

Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Noble BA, Loh RS, MacLennan S, Pesudovs K, Reynolds A, Bridges LR, Burr J, Stewart O, Quereshi S. Br J Ophthalmol. 2004 May;88(5):647-52. doi: 10.1136/bjo.2003.026211. PMID: 15090417; PMCID: PMC1772131.

The Royal College of Ophthalmologists guidelines on serum eye drops for the treatment of severe ocular surface disease: full report. Rauz S, Koay SY, Foot B, Kaye SB, Figueiredo F, Burdon MA, Dancey E, Chandrasekar A, Lomas R. Eye (Lond). 2017 Nov 17. doi: 10.1038/eye.2017.209. Epub ahead of print. PMID: 29148532.

Autologous serum eye drops for dry eye. Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Cochrane Database Syst Rev. 2017 Feb 28;2(2):CD009327. doi: 10.1002/14651858.CD009327.pub3. PMID: 28245347; PMCID: PMC5510593.

Serum eye drop preparation in Australia: Current manufacturing practice. Marks DC, Fisher J, Mondy P, Segatchian J, Dennington PM. Transfus Apher Sci. 2015 Aug;53(1):92-4. doi: 10.1016/j.transci.2015.05.015. Epub 2015 Jun 9. PMID: 26123029.

Allogeneic and autologous serum eye drops: a pilot double-blind randomized crossover trial. van der Meer PF, Verbakel SK, Honohan Á, Lorinser J, Thurlings RM, Jacobs JFM, de Korte D, Eggink CA. Acta Ophthalmol. 2021 Dec;99(8):837-842. doi: 10.1111/aos.14788. Epub 2021 Feb 15. PMID: 33590715; PMCID: PMC9544559.

Amniotic membrane extract eye drops: a new approach to severe ocular surface pathologies. Pérez ML, Barreales S, Sabater-Cruz N, Martinez-Conesa EM, Vilarrodona A, Casaroli-Marano RP. Cell Tissue Bank. 2022 Sep;23(3):473-481. doi: 10.1007/s10561-021-09962-4. Epub 2021 Sep 21. PMID: 34549352.

Clinical evaluation of allogeneic eye drops from cord blood platelet lysate. Samarkanova D, Martin S, Bisbe L, Puig J, Calatayud-Pinuaga M, Rodriguez L, Azqueta C, Coll R, Casaroli-Marano R, Madrigal A, Rebulla P, Querol S; Barcelona CBED Study Group (Appendix I). Blood Transfus. 2021 Jul;19(4):347-356. doi: 10.2450/2020.0130-20. Epub 2020 Oct 9. PMID: 33085593; PMCID: PMC8297669.

A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease. Sugar A, Hussain M, Chamberlain W, Dana R, Kelly DP, Ta C, Irvine J, Daluvoy M, Perez V, Olson J, Jhanji V, Walts TA, Stulting RD, Waller EK, Jagirdar N; Cambium Dry Eye Study Group. Ophthalmol Sci. 2022 Jun 2;2(3):100176. doi: 10.1016/j.xops.2022.100176. PMID: 36245754; PMCID: PMC9562362. 

Publication on Workshop results

Eye drops of human origin-Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies. Gabriel, C., Marks, D. C., Henschler, R., Schallmoser, K., Burnouf, T., & Koh, M. B. C. (2023). Vox Sanguinis, 118(4), 301–309.

Chairs

Christian Gabriel

Christian Gabriel

Vice Chair of the Cellular Therapies Working Party, Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria

Denese Marks

Denese Marks

ISBT Regional Director Western Pacific, ISBT BC WP Chair, Associate Professor, University of Sydney, Australia; Australian Red Cross LifeBlood Service

 

Members

Pieter van der Meer, Joanne Tan, Anika Mahmood, Olga Lamprecht, Arwa Al Riyamy, Melanie Störmer, Lilach Bonstein, Riana Cockeran

Human Platelet Lysate subgroup

Work plan 2024-2025
  • Establish subgroup working structure including new members
  • Involve YPs:
  • Metaanalysis on HPL therapeutic efficiency
  • Analyse options to involve research and experts for EV
  • Survey in ISBT members:  
    • Who uses HPL in clinical applications?
    • Supply of expired platelets, including day 7 PLT extension, use of buffy coats, numbers of outdated PLT units?
    • Data on what HPL is used for?
Workshop

The workshop was held on March 22-23, 2018 in Zurich to provide a forum for transfusion experts who manufacture the product, scientists who are investigating its therapeutic and cell culture potential to discuss the latest updates on the field, and also with the regulators on how to classify this blood derived product.

Click here for the programme of the workshop.

Manuscript on Workshop results
  1. Human platelet lysate current standards and future developments. Henschler R, Gabriel C, Schallmoser K, Burnouf T, Koh MBC.Transfusion. Transfusion, 2019 Apr;59(4):1407-1413. doi: 10.1111/trf.15174. Epub 2019 Feb 11.

Literature

References Platelet lysates

  1. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization. Wu, Y. W., Lee, D. Y., Lu, Y. L., Delila, L., Nebie, O., Barro, L., Changou, C. A., Lu, L. S., Goubran, H., & Burnouf, T. (2023). Platelets, 34(1), 2237134.

  2. Blood-brain crosstalk: the roles of neutrophils, platelets, and neutrophil extracellular traps in neuropathologies. Chou, M. L., Babamale, A. O., Walker, T. L., Cognasse, F., Blum, D., & Burnouf, T. (2023). Trends in neurosciences, 46(9), 764–779.

  3. Transcription Factors STAT3 and MYC Are Key Players of Human Platelet Lysate-Induced Cell Proliferation. Oeller, M., Jaksch-Bogensperger, H., Templin, M., Gehwolf, R., Rohde, E., Schallmoser, K., & Laner-Plamberger, S. (2022). International journal of molecular sciences, 23(24), 15782. 

  4. Synergy of Human Platelet-Derived Extracellular Vesicles with Secretome Proteins Promotes Regenerative Functions. Gomes, F. G., Andrade, A. C., Wolf, M., Hochmann, S., Krisch, L., Maeding, N., Regl, C., Poupardin, R., Ebner-Peking, P., Huber, C. G., Meisner-Kober, N., Schallmoser, K., & Strunk, D. (2022). Biomedicines, 10(2), 238.

  5. Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis. Gouel, F., Timmerman, K., Gosset, P., Raoul, C., Dutheil, M., Jonneaux, A., Garçon, G., Moreau, C., Danel-Brunaud, V., Duce, J., Burnouf, T., Devedjian, J. C., & Devos, D. (2022). Biomaterials, 280, 121311.

  6. Can the administration of platelet lysates to the brain help treat neurological disorders? Nebie, O., Buée, L., Blum, D., & Burnouf, T. (2022). Cellular and molecular life sciences : CMLS, 79(7), 379. 

  7. Prospective Therapeutic Applications of Platelet Extracellular Vesicles. Johnson, J., Wu, Y. W., Blyth, C., Lichtfuss, G., Goubran, H., & Burnouf, T. (2021). Trends in biotechnology, 39(6), 598–612.

  8. The multifaceted role of platelets in mediating brain function. Burnouf, T., & Walker, T. L. (2022). Blood, 140(8), 815–827.

  9. Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production. Oeller, M., Laner-Plamberger, S., Krisch, L., Rohde, E., Strunk, D., & Schallmoser, K. (2021). International journal of molecular sciences, 22(10), 5178.

  10. A purified human platelet pellet lysate rich in neurotrophic factors and antioxidants repairs and protects corneal endothelial cells from oxidative stress. R., Burnouf, T., Nebie, O., Delila, L., & Wang, T. J. (2021). Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 142, 112046.

  11. Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment. Nebie, O., Carvalho, K., Barro, L., Delila, L., Faivre, E., Renn, T. Y., Chou, M. L., Wu, Y. W., Nyam-Erdene, A., Chou, S. Y., Buée, L., Hu, C. J., Peng, C. W., Devos, D., Blum, D., & Burnouf, T. (2021). Brain : a journal of neurology, 144(10), 3142–3158.

  12. Heat-treated human platelet pellet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation in vitro. Nebie, O., Barro, L., Wu, Y. W., Knutson, F., Buée, L., Devos, D., Peng, C. W., Blum, D., & Burnouf, T. (2021). Platelets, 32(2), 226–237. 

  13. Extensive characterization of the composition and functional activities of five preparations of human platelet lysates for dedicated clinical uses. Delila L, Wu Y-W, Nebie O, Widyaningrum R, Chou M-L, Devos D, Burnouf T Platelets, 05 Sep 2020, Accepted 26 Oct 2020, Published online: 27 Nov 2020
  14. Human platelet lysates for human cell propagation. Barro L, Burnouf P-A, Chou M-L, Nebie O, Wu Y-W, Chen M-S, Radosevic M, Knutson F, Burnouf T Platelets, 26 Aug 2020, Accepted 23 Oct 2020, Published online: 29 Nov 2020
  15. Nanofiltration of growth media supplemented with human platelet lysates for pathogen-safe xeno-free expansion of mesenchymal stromal cells. Barro L, Nebie O, Chen M-S, Wu YW, Koh MBC, Knutson F., Watanabe N, Takahara M, Burnouf T Cytotherapy 2020; 22:458-472.
  16. Heat-treated human platelet pellet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation in vitro. Nebie O, Barro L, Wu YW, Knutson F, Buée L, Devos D, Peng CW, Blum D*, Burnouf T Platelets, 07 Dec 2019, Accepted 13 Feb 2020, Published online: 27 Feb 2020
  17. Production and quality Requirements of human platelet lysate: A Position Statement from the working party on cellular therapies of the International Society of Blood Transfusion. Schallmoser K, Henschler R, Gabriel C, Koh MBC, Burnouf T Trends in Biotechnology, 2020;38:13-23.
  18. The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. Nebie O, Devos D, Vingtdeux V, Barro L, Devedjian JC, Jonneaux A, Chou ML, Bordet R, Buée L, Knutson F, Blum D, Burnouf T. Journal of Biomedical Science, 2019; 26, 89. doi:10.1186/s12929-019-0579-9
  19. Virus safety of human platelet lysate for cell therapy and regenerative medicine: moving forward yes, but without forgetting the past. Burnouf T, Barro L, Nebie O, Wu Y-W, Goubran H, Knutson F, Segatchian J.Transfusion and Apheresis Science 2019; 58:102674
  20. Effect of human platelet lysate on the differentiation ability of human adipose-derived stem cells cultured on ECM-coated surfaces. Gao Y, Ku N-J, Sunb T-C, Higuchi A, Hung C-S, Lee H H-C, Ling Q-D, Cheng N-C, Umezawa A, Barro L, Burnouf T, Ye Q, Chen H. Journal of Materials Chemistry B 2019 Dec 7;45:7110-7119
  21. Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates. Gouel F, Rolland A-S, Devedjian JC, Burnouf T, Devos D. Frontiers in Neurology, August 2019, 10, Article 835. doi: 10.3389/fneur.2019.00835.
  22. A double virally-inactivated (Intercept-solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells. Barro, L, Su YT, Nebie Oc, Wuc YW, Huang YH, Koh MB, Knutson F, Burnouf T*. Transfusion, 2019; 59:2061-2073

Chairs

Katharina Schallmoser

Katharina Schallmoser

Professor for Transfusion Medicine, Paracelsus Medical University Salzburg, Austria

Thierry Burnouf

Thierry Burnouf

Global Blood Safety Working Party Secretary, Cellular Therapies Treasurer, Vice-Dean, Taipei Medical University, Taiwan

Members

Zbigniew Szczepiorkowski, Anika Mahmood, Olga Lamprecht, Divjot Singh Lamba, Rishiraj Sinha, Riana Cockeran, Michaela Oeller, Ming Li. 

Apheresis subgroup

Work plan 2024-2026

  • Establish new members (ongoing)                 
  • Webinar (2024-25)       
  • Educational session at the ISBT congress (2025)
  • Recommendations and minimal requirements that can be used as aide-memoire / applicable to all cellular therapies (2026)
  • One-day meeting (2026)
  • Publications reviewing central themes of the WP work (ongoing)

Chairs

Nina Worel, Yossi Schwartz, Hans Vrielink

Members

Saikat Mandal, Rounak Dubey, Mickey Koh, Melanie Störmer, Arwa Al-Ryiami, Mohandoss Murugesan, Beate Wagner, Anika Mahmood, Nittin Henry, Divjot Singh Lamba, Tanya Glatt, Olga Lamprecht, Hugo Fabre, Divjot Singh Lamba, Bala Bhasker, Christoph Grabmer, Francis Swaneveld. 

Guide to set up a GMP facility for Stem Cell Processing

  1. Essential requirements for setting up a stem cell processing laboratory T Leemhuis, D Padley, C Keever-Taylor, D Niederwieser, T Teshima, F Lanza, C Chabannon, P Szabolcs, A Bazarbachi, MBC Koh, on behalf of the Graft Processing Subcommittee of the Worldwide Network for Blood and Bone Marrow Transplantation (WBMT) Bone Marrow Transplant 49, 1098–1105 (2014).